

Preliminary findings show no benefits of Remdesivir, Hydroxychloroquine for COVID-19



New York, April 28 (RHC)-- A draft manuscript of a report from a long-awaited clinical trial in China finds the antiviral drug remdesivir failed to lower the death rates or recovery times of COVID-19 patients. The findings have not yet passed peer review.

Preliminary results of a study by the New York state Department of Health showed the drug touted by President Trump as a curative for COVID-19 — hydroxychloroquine — had no effect on patients' recoveries.

<https://www.radiohc.cu/index.php/en/noticias/internacionales/221147-preliminary-findings-show-no-benefits-of-remdesivir-hydroxychloroquine-for-covid-19>



Radio Habana Cuba